CN106674319B - Compound for treating hepatitis C - Google Patents

Abstract

The invention discloses a compound shown as the following formula or a medicinal salt thereof:

Description

Compound for treating hepatitis C

Technical Field

The invention belongs to the field of medicines, relates to a medicine for treating hepatitis C, and particularly relates to a compound, and a preparation method and application thereof.

Background

Sofosbuvir (Sofosbuvir) is an NS5B polymerase inhibitor, developed by Pharmasset, purchased by gillidde (Gilead) in 2011, and developed by gillide to market as a drug for the treatment of hepatitis c. The drug was approved by the FDA in the united states in 2013 at 12 months as part of an antiviral treatment regimen for the treatment of chronic Hepatitis C (HCV) under the trade name Sovaldi. Sofosbuvir is the first approved drug for use in a full oral hepatitis c treatment regimen, eliminating the need for the traditional injected drug interferon when used in the treatment of chronic hepatitis c of a particular genotype. The structure of sofosbuvir is as follows:

。

although sofosbuvir has a good effect of treating hepatitis C, the treatment cost is extremely high, and the compound patent is as long as 2030 years in China due date, Chinese hepatitis C patients cannot receive relatively cheap imitation drug treatment early, so that the research and development of good drugs for treating hepatitis C with independent intellectual property rights are urgently needed, so that the patients can receive relatively reasonable drug treatment early.

Disclosure of Invention

The invention aims to provide a medicine for treating hepatitis C, so that Chinese patients can receive the medicine for treating hepatitis C with relatively reasonable price and independent intellectual property rights.

The sofosbuvir analogue disclosed by the invention has the effect of treating hepatitis C better than that of sofosbuvir, has the toxic and side effects similar to those of sofosbuvir, and has no obvious adverse reaction.

In one aspect, the invention provides the following sofosbuvir analogue BG40204 or a pharmaceutically acceptable salt thereof:

BG40204。

in another aspect of the invention there is provided the use of the compound: use in the manufacture of a medicament for use as an inhibitor of NS5B polymerase; use in the manufacture of a medicament for a hepatitis c virus-associated disease and/or condition; use in the manufacture of a medicament for hepatitis c virus infection.

In a third aspect, the invention provides a process for the preparation of the compound:

。

in a fourth aspect, the present invention provides a composition comprising a compound as described above, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.

In a fifth aspect, the present invention provides the use of the above composition: use in the manufacture of a medicament for use as an inhibitor of NS5B polymerase; use in the manufacture of a medicament for a hepatitis c virus-associated disease and/or condition; use in the manufacture of a medicament for hepatitis c virus infection.

Among the numerous sofosbuvir analogues, the compound of the present invention has unexpectedly been found to be more active as a compound having the following structure:

BG40200。

however, the activity of the compound is still not better than that of sofosbuvir, and the BG40200 is a racemate, so the configuration of chiral phosphorus has an influence on the activity.

The skilled person of the present invention unexpectedly finds that the anti-HCV (hepatitis c virus) activity of the compound of the present invention is better than sofosbuvir, and further better than its isomer BG 40205:

BG40205。

when the configuration of the compound BG40202 phosphate is the (S) configuration, the activity is better than that of BG40205 in the (R) configuration.

Drawings

FIG. 1: BG40204 and positive controls were fitted with curves for toxicity to HCV GT1b replicon cells and for HCV replicon dose-dependent Inhibition (% Inhibition) activity (% viatility).

FIG. 2: GS-7977 and the positive control were fitted to curves for toxicity to HCV GT1b replicon cells and for HCV replicon dose-dependent Inhibition (% Inhibition) activity (% viatility).

FIG. 3: BG40204 Positive ion Mass Spectrometry MS (ESI)⁺,m/e)：592。

FIG. 4: BG40204 negative ion Mass Spectrometry MS (ESI)^-,m/e)：590。

FIG. 5: BG40204 Hydrogen Spectrum¹H –NMR。

DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION

Example 1 Synthesis of BG40204

；

Synthesis of Compound 2

Under nitrogen protection, 10g (52.8 mmol, 1.0 eq) of Boc-L-alanine was added to a 500mL three-necked flask, followed by addition of 200mL of dichloromethane, and the mixture was stirred at room temperature until it became clear. Then, the temperature was lowered to-5 ℃ and 10.9g (52.8 mmol, 1.0 eq) of DCC was added, and the reaction solution was transferred to a chamberThe reaction was stirred for 2 hours. Then, 7.75g (63.4 mmol, 1.2 eq) of p-methylbenzyl alcohol was added thereto, and the mixture was stirred at room temperature for 24 hours. Filtering, sequentially adding water and saturated NaHCO into filtrate₃The solution, 1M hydrochloric acid solution, saturated sodium chloride solution washing. The layers were separated, and the resulting organic phase was dried over anhydrous sodium sulfate for 2 hours. Filtration, rotary evaporation and concentration gave 24.9g of pale solid compound 2.

Synthesis of Compound 3

Under nitrogen protection, 23.6g (28.35 mmol, 0.9 eq) of compound 2 was added to a 500mL three-necked flask, followed by addition of 50mL ethyl acetate and stirring to obtain a cloudy solution. The suspension was cooled to 0 ℃ and 100mL of ethyl acetate/hydrochloric acid (6N) solution was added. After the dropwise addition, the reaction solution was allowed to cool to room temperature and stirred for 30 min. And (5) performing rotary evaporation to dryness to obtain an oily substance. Adding 100mL of water, adjusting the pH value to be 2 by using a 1N HCl solution, extracting by using ethyl acetate for three times, and discarding an organic phase. And adjusting the pH value of the water phase by using 1M sodium hydroxide solution to be 8, extracting the water phase by using ethyl acetate for three times, washing the obtained organic phase once by using saturated sodium chloride solution, and drying the organic phase for 2 hours by using anhydrous sodium sulfate. Filtered, evaporated and concentrated to give 15.0g of oily liquid 3.

Synthesis of Compound 4

Under nitrogen protection, 16.17g (83.7 mmol, 1.0 eq) of compound 3 was added to a 500mL three-necked flask, 100mL of dichloromethane was added, and the mixture was stirred at room temperature to dissolve. Then the temperature is reduced to minus 80 ℃, 17.7g (83.7 mmol, 1.0 eq) of phenyl dichlorophosphate is added dropwise, and the temperature is controlled not to exceed minus 70 ℃ in the dropwise adding process. After the completion of the addition, a solution of 17.0g (167 mmol, 2.0 eq) of triethylamine in methylene chloride (40 mL) was added dropwise. The reaction mixture was allowed to warm to room temperature and stirred for 2 hours. Then, the temperature was reduced to 0 ℃ and a solution of 15.4g (83.7 mmol, 1.0 eq) of pentafluorophenol in methylene chloride (40 ml) was added dropwise. A solution of 17.0g (167 mmol, 2.0 eq) triethylamine in dichloromethane (40 mL) was added dropwise. The reaction temperature was controlled at 0 ℃ and the reaction was stirred for 3 hours. Filtering, and spin-drying the obtained filtrate to obtain oily substance. Purifying by column chromatography (PE/EA =1: 1), collecting pure product part, and spin-drying to obtain light-colored solid.

To the solid, 300mL of ethyl acetate was added, and the mixture was stirred at room temperature to dissolve it, and 900mL of petroleum ether was added to precipitate a solid. Filtration and drying gave 20.0g of white solid 4.

Synthesis of BG40204

Under nitrogen protection, 6.1g (23.3 mmol, 1.0 eq) of 2 ' -deoxy-2 ' -fluoro-2 ' -methyl-uracil was added to a 500mL three-necked flask, and 75mL of anhydrous THF was added thereto, followed by stirring at room temperature until it was clear. Then the temperature is reduced to-15 ℃, 70mL (70 mmol, 3.0 eq) of 1M t-BuMgCl/THF solution is added dropwise, the temperature of the reaction solution is raised to room temperature after the dropwise addition is finished, and the reaction solution is stirred for reaction for 4 hours. 19.4g (35 mmol, 1.5 eq) of Compound 4 was added in 6 portions over 12 hours and the reaction was monitored by TLC until no Compound 4 remained. After the reaction, a saturated ammonium chloride solution was poured into the reaction solution to quench the reaction. The THF was removed by concentration in vacuo, the resulting solution was extracted three times with ethyl acetate, the layers were separated, the organic phase was washed once with saturated sodium chloride, and dried over anhydrous sodium sulfate for 2 hours. Filtered, concentrated by rotary evaporation to give a pale solid, and 15.3g was weighed.

To the solid was added 150mL of ethyl acetate, and the mixture was heated to reflux and the solid was clear. Then 150mL of tert-butyl methyl ether is added, the temperature is reduced to room temperature, and the mixture is stirred and crystallized overnight. Filtration and drying gave 13.2g of the title compound as a white solid.

MS(ESI⁺,m/e)：592

MS(ESI^-,m/e)：590

¹H NMR：8.31 (1H, s), 7.43-7.16 (9H, m), 6.17 (1H, d), 5.69(1H, d),5.12 (2H, s), 4.54-4.50 (1H, m), 4.49-4.41 (1H, m), 4.10-3.76 (3H, m), 3.58-3.56 (1H, m), 2.35 (3H, s), 1.61-1.36 (6H, m)

Example 2

The following are pharmacological tests of the compounds of the invention in comparison with sofosbuvir:

BG40204, BG40205, BG40200 are as defined above; GS-7977 is a standard sofosbuvir bulk drug provided by pharmacology research and development companies as a reference.

1. Purpose of study

anti-HCV replicon activity assays were performed on 3 compounds from Borui biomedical (Suzhou) Inc. using the Hepatitis C Virus (HCV) genotype 1b replicon cell system. GS-7977 was used as a positive control in the experiment.

2 materials of experiment

2.1 HCV 1b replicon cells, the Huh7 cell line, was stably transformed with the HCV genotype 1b replicon.

2.2 test Compounds: prepared from Bory biomedical technology (Suzhou) Ltd in 100% DMSO to prepare 20 mM stock solution for temporary storage in nitrogen gas cabinet.

2.3 reagent: see table 1.

TABLE 1 list of reagents

。

3. Experimental methods

3.1 treatment with Compound: compound DMSO stock was diluted, three-well and added to 96-well assay plates according to compound dilution information in table 2. The final concentration of DMSO in the cell culture broth was 0.5%.

TABLE 2 Compound List

。

3.2 cell treatment: HCV-1b replicon cells (8,000 cells/well) were seeded in the above 96-well cell plate, followed by incubation at 37 ℃ with 5% CO₂Culturing in an incubator for 3 days.

3.3 cell activity assay: adding cell growth fluorescent titration detection reagent into each hole, and adding 5% CO at 37 deg.C₂After culturing the cells in the incubator for 1 hour, the luminousnce signal value was measured by spectrophotometry, and the raw data (RFU) was used for compound cytotoxicity calculation.

3.4 anti-HCV replicon activity assay: luciferase luminescent substrate Bright-Glo was added to each well and Luminescence signal values were measured within 5 minutes using the chemiluminescence detection System Envision and raw data (RLU) was used for compound inhibition activity calculations.

3.5, data processing: raw data were processed as percent cell viability using the following formula:

raw data were processed as percent inhibition using the following formula:

CPD (CPD): signal value of compound pore

HPE (Hundred percent effect) 100% effective control well signal value, only DMEM culture solution in the well

ZPE (zero percent effect) null effect control well signal values, replacement of compound with 0.5% DMSO

Respectively introducing the cell viability percentage and the cell inhibition percentage into GraphPad Prism software for data processing to obtain a curve corresponding to the compound and the cytotoxicity (CC) of the compound₅₀) And inhibitory Activity on HCV replicon (EC)₅₀) Numerical values.

4. Experimental results and discussion

TABLE 3 EC of compounds against HCV GT1b replicon cells₅₀And CC₅₀Value of

。

Compounds BG40204, BG40205, BG40200 show varying degrees of inhibitory activity on HCV replicons, with their EC₅₀The values were 0.042. mu.M, 0.397. mu.M and 0.174. mu.M, respectively. And all tested compounds showed no cytotoxicity, CC, in the range of concentrations determined₅₀The values are all greater than the highest detected concentration.

The figure shows the toxicity of test compounds and positive controls against HCV GT1b replicon cells and a curve fitted to the dose-dependent inhibitory activity of HCV replicons.

From the results, it was found that the activity of the compound BG40204 of the present invention is superior to that of the racemic compound BG40200 (EC)₅₀0.042 vs 0.174), far superior to its isomer BG40205 (EC)₅₀0.042 vs 0.397) and is also superior to sofosbuvir (EC)₅₀0.042 vs 0.124) and is in the range of the determined concentrationNone of them showed cytotoxicity, CC₅₀The values are all greater than the highest detected concentration.

Claims (9)

1. A compound of the formula:

2. use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is: use in the manufacture of a medicament for use as an inhibitor of NS5B polymerase.

3. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is: use in the manufacture of a medicament for the treatment of a hepatitis C virus-related disease and/or condition.

4. Use of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is: use in the manufacture of a medicament for hepatitis c virus infection.

5. A process for the preparation of a compound according to claim 1, or a pharmaceutically acceptable salt thereof, which is

6. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier.

7. The use of the pharmaceutical composition of claim 6, which is: use in the manufacture of a medicament for use as an inhibitor of NS5B polymerase.

8. The use of the pharmaceutical composition of claim 6, which is: use in the manufacture of a medicament for the treatment of a hepatitis C virus-related disease and/or condition.

9. The use of the pharmaceutical composition of claim 6, which is: use in the manufacture of a medicament for hepatitis c virus infection.

Images